NCT02950766View on ClinicalTrials.gov

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 3, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

May 30, 2030

Conditions
Kidney Cancer
Interventions
DRUG

NeoVax

combination of Neoantigen peptides and poly-ICLC

DRUG

Ipilimumab

local administration of ipilimumab

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Oncovir, Inc.

INDUSTRY

lead

Patrick Ott, MD, PhD

OTHER